Cell Therapeutics Inc. Newsletter
-
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript
01 Apr 2025 13:10 GMT
… projections regarding BrainStorm Cell Therapeutics and its potential … Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Follow Brainstorm Cell Therapeutics Inc. … Follow Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Follow Brainstorm Cell Therapeutics Inc. …
-
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
07 Apr 2025 12:05 GMT
… and allogeneic natural killer (NK) cell therapeutics, today announced the oral presentation … innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa …
-
Brainstorm Cell Therapeutics Granted Compliance Extension From Nasdaq
26 Mar 2025 14:35 GMT
… Chief Executive Officer of BrainStorm Cell Therapeutics, commented: "We take … as warranted.
About BrainStorm Cell Therapeutics Inc .
BrainStorm Cell Therapeutics Inc. is a … protected]
Logo:
SOURCE BrainStorm Cell Therapeutics Inc.
WANT YOUR COMPANY…
-
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript
11 Mar 2025 12:29 GMT
… March 10, 2025
Lineage Cell Therapeutics, Inc. beats earnings expectations …
Follow Lineage Cell Therapeutics Inc. (NYSE:LCTX) Follow Lineage Cell Therapeutics Inc. …
Follow Lineage Cell Therapeutics Inc. (NYSE:LCTX) Follow Lineage Cell Therapeutics Inc. ( …
-
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
10 Mar 2025 22:52 GMT
… .
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical … these cautionary statements.
LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES
… ,193
172,663
LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS …
-
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
05 Mar 2025 13:21 GMT
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: … and should request the “Lineage Cell Therapeutics Call”. A live webcast of … number 6707203.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage …
-
Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury
13 Feb 2025 08:53 GMT
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology … of Change (CGI-C).
Lineage Cell Therapeutics is a clinical-stage biotechnology …
-
MaxCyte inks strategic platform license agreement with TG Therapeutics to advance its autoimmune cell therapeutics programmes
13 Feb 2025 04:54 GMT
MaxCyte, Inc, a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, announced they are entering into a strategic platform …
-
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
12 Feb 2025 07:00 GMT
ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation …
-
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
04 Feb 2025 16:34 GMT
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: … Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage …
About
© 1995-2025